Ken Griffin Century Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.44 - $3.29 $14,256 - $32,571	9,900 Added 3300.0%	10,200 $17,000
Q1 2024 May 15, 2024	SELL	$3.19 - $5.32 $319 - $532	-100 Reduced 25.0%	300 $1,000
Q4 2023 Feb 14, 2024	SELL	$1.28 - $3.32 $1,664 - $4,316	-1,300 Reduced 76.47%	400 $1,000
Q3 2023 Nov 14, 2023	BUY	$2.0 - $3.23 $3,200 - $5,168	1,600 Added 1600.0%	1,700 $3,000
Q2 2023 Aug 14, 2023	SELL	$2.91 - $3.53 $5,820 - $7,060	-2,000 Reduced 95.24%	100 $0
Q1 2023 May 15, 2023	SELL	$3.4 - $5.11 $680 - $1,022	-200 Reduced 8.7%	2,100 $7,000
Q4 2022 Feb 14, 2023	BUY	$4.84 - $11.58 $11,132 - $26,634	2,300 New	2,300 $11,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $96M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.